Werewolf posts $3.7 million Q2 net income on $21.0 million collaboration revenue
Werewolf Therapeutics reported second quarter 2026 net income of $3.7 million, compared with a net loss of $18.0 million a year earlier, driven by $21.0 million of collaboration revenue tied to the sale of its JZP898 program to Jazz Pharmaceuticals Ireland Limited. Cash and cash equivalents fell to $22.0 million at June 30, 2026, and the company expects to fund operations into the second quarter of 2027, so shareholders should weigh the one-time revenue against the lower cash balance and the ongoing strategic alternatives process.
Key points
- Net income was $3.7 million for Q2 2026, versus a net loss of $18.0 million in Q2 2025.
- Collaboration revenue was $21.0 million in Q2 2026, from the JZP898 asset sale to Jazz; no collaboration revenue was recognized in Q2 2025.
- Cash and cash equivalents were $22.0 million at June 30, 2026, down from $46.5 million at March 31, 2026; the company expects to fund operations into Q2 2027.
- The company is running a strategic alternatives process with Piper Sandler & Co. and expects updates in the second half of 2026.
The filing
Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 31, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.